Filter by
Westborough, Mass., March 3, 2021 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the targeted inhibition of coagulation Factor XIa, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial […]
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
Clinical and preclinical data published in Critical Care Explorations demonstrate that EP-7041 has the ability to inhibit ECMO-related thrombosis while minimizing the risk of unwanted bleeding Westborough, Mass., Sept. 17, 2020 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the inhibition of coagulation […]
Anticoagulation with the Novel, Small-molecule Factor XIa (fXIa) Antagonist, EP-7041, Prevents Oxygenator Clotting but Conserves Hemostasis in a Canine Extracorporeal Circulation (ECMO) Model
Poster
Phase 1a/1b Study of EP-7041: A Novel, Potent, Selective, Small Molecule FXIa Inhibitor
Phase 1 results suggest the PK/PD profile of EP-7041 is ideal in acute care hospital settings where patients are at risk of thromboembolic events.
Download as PDF